SillaJen and ABL Europe extends strategic Manufacturing collaboration
Clinical-stage, biotherapeutics company, SillaJen committed to the development of oncolytic immunotherapy products for Cancer and ABL Europe company providing dedicated viral vector GMP services for gene therapy , oncolytic products and vaccines for all stages of clinical supply have extended strategic manufacturing collaboration.
Georg Roth, Ph.D, Senior Vice President, Technical Operations at SillaJen stated “ABL has significant experience in virus manufacturing, and we are glad to be able to utilize their expertise in order to continue to expedite the development of these important oncolytic virus therapies.”
Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen’s pipeline product, JX-970. The ongoing Phase 3 study, named the PHOCUS trial, is designed to enroll 600 patients who have not received prior systemic treatment for their cancer.
Pexa-Vec is the most advanced product candidate from SillaJen’s proprietary SOLVE (Selective Oncolytic Vaccinia Engineering) platform. The vaccinia strain backbone of Pexa-Vec has been used safely in millions of people as part of a worldwide vaccination program.